BioMarker Strategies was recently awarded an additional NCI SBIR contract to develop companion diagnostic test and raises $2.3M in investments.  HS Design was hired by BioMarker Strategies to work on the development of user research, usability, design and development for both the SnapPath™ Platform  including the instrument, Graphical user interface (GUI) and injection molded disposable cartridge.  The program will see HS Design working with BioMarker Strategies towards the complete development of its benchtop instrument for clinical trials and commercial release. The SnapPath™ biomarker testing system* is an automated live tumor cell processing platform that enables next-generation predictive tests—known as Functional Signaling Profiles (FSPs)—to guide targeted drug therapy selection for individual cancer patients.